Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) had its target price upped by Cantor Fitzgerald from $24.00 to $30.00 in a report released on Thursday morning, The Fly reports.
Several other research firms have also weighed in on AUPH. Oppenheimer upped their price target on Aurinia Pharmaceuticals from $14.00 to $22.00 in a research report on Thursday. Bloom Burton restated a buy rating on shares of Aurinia Pharmaceuticals in a research report on Wednesday, October 2nd. ValuEngine cut Aurinia Pharmaceuticals from a strong-buy rating to a buy rating in a research note on Thursday, October 10th. Zacks Investment Research raised Aurinia Pharmaceuticals from a sell rating to a hold rating in a research note on Thursday, November 28th. Finally, Citigroup began coverage on Aurinia Pharmaceuticals in a report on Monday, September 9th. They issued an outperform rating and a $14.00 target price on the stock. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Aurinia Pharmaceuticals currently has an average rating of Buy and a consensus target price of $18.46.
NASDAQ AUPH opened at $15.44 on Thursday. The firm’s 50 day moving average price is $6.08 and its two-hundred day moving average price is $6.03. Aurinia Pharmaceuticals has a twelve month low of $3.52 and a twelve month high of $17.48. The stock has a market cap of $1.46 billion, a price-to-earnings ratio of -20.32 and a beta of 1.25.
Several large investors have recently modified their holdings of the business. BlackRock Inc. increased its stake in shares of Aurinia Pharmaceuticals by 3.1% in the second quarter. BlackRock Inc. now owns 921,425 shares of the biotechnology company’s stock worth $6,063,000 after acquiring an additional 28,129 shares during the last quarter. Toronto Dominion Bank boosted its position in Aurinia Pharmaceuticals by 26.3% during the second quarter. Toronto Dominion Bank now owns 12,355 shares of the biotechnology company’s stock valued at $81,000 after purchasing an additional 2,575 shares during the last quarter. A.R.T. Advisors LLC grew its stake in Aurinia Pharmaceuticals by 44.9% in the second quarter. A.R.T. Advisors LLC now owns 18,395 shares of the biotechnology company’s stock valued at $121,000 after purchasing an additional 5,700 shares in the last quarter. SG Americas Securities LLC purchased a new position in Aurinia Pharmaceuticals in the third quarter valued at about $246,000. Finally, Benjamin F. Edwards & Company Inc. grew its stake in Aurinia Pharmaceuticals by 42.9% in the third quarter. Benjamin F. Edwards & Company Inc. now owns 10,000 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 3,000 shares in the last quarter. 32.06% of the stock is owned by institutional investors.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.
Recommended Story: High-Yield Dividend Stocks
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.